Compare LYFT Inc (LYFT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? LYFT Inc trades at $16.36 (market cap $6.20B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: LYFT Inc is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 48 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LYFT | TVTX | |
|---|---|---|
Market Cap | $6.20B | $4.88B |
Volume | 12,306,511 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $24.57 | $67.52 |
52-Week Low | $12.65 | $26.79 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $5.67B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft (LYFT) trades at $16.48, up 2.3% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 2.38 and net income margin of 42.32%. Recent developments include European expansion and a $272.5M legal settlement. Cash flow improved significantly to $891M in 2025 from negative levels in prior years, while revenue grew to $6.32B.
Outlook remains positive with analyst consensus target of $18.07, though mixed earnings performance and regulatory risks persist. The stock offers value with low valuation multiples but faces competition and execution challenges in international markets. Recent technical indicators show overbought conditions near resistance at $17.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
